Article Text
DTB Select
Rivaroxaban plus aspirin for secondary prevention
Statistics from Altmetric.com
Aspirin is well established in the secondary prevention of cardiovascular disease. In a meta-analysis of 16 secondary prevention trials (17,000 participants), aspirin has been shown to reduce serious vascular events (6.7% vs 8.2% per year, p<0.0001) with reductions in total stroke (2.08% vs 2.54% per year, p=0.002) and in coronary events (4.3% vs. 5.3% per year, p<0.0001).1 A trial has assessed whether rivaroxaban alone or in combination with aspirin is more …